# Irinotecan in Treating Patients With Colorectal Cancer

> **NCT00003843** · — · TERMINATED · sponsor: **California Cancer Consortium** · enrollment: 28 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** irinotecan hydrochloride
- **GENETIC:** mutation analysis
- **GENETIC:** polymorphism analysis

## Key facts

- **NCT ID:** NCT00003843
- **Lead sponsor:** California Cancer Consortium
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 1998-10
- **Primary completion:** 2001-02
- **Final completion:** 2001-02
- **Target enrollment:** 28 (ESTIMATED)
- **Why stopped:** Study terminated due to poor accrual
- **Last updated:** 2015-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003843, "Irinotecan in Treating Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00003843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*